Poseida Therapeutics, Inc. (PSTX)

Market Cap	265.10M
Revenue (ttm)	150.86M
Net Income (ttm)	-60.76M
Shares Out	97.47M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	434,467
Open	2.800
Previous Close	2.770
Day's Range	2.635 - 2.820
52-Week Range	1.870 - 4.270
Beta	0.54
Analysts	Strong Buy
Price Target	15.00 (+451.47%)
Earnings Date	Nov 7, 2024

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple my...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 330
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTX
• Website: https://poseida.com

Financial Performance

In 2023, Poseida Therapeutics's revenue was $64.70 million, a decrease of -50.42% compared to the previous year's $130.49 million. Losses were -$123.43 million, 92.9% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for PSTX stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 451.47% from the latest price.

Price Target

$15.0

(451.47% upside)

Analyst Consensus: Strong Buy